← 產業報告目錄

Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-03-25頁數 451報告編號 PH5682

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global drug discovery services market is anticipated to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025, with a significant CAGR of 10.7%. The market is growing strongly at a considerable CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on the rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players are likely to witness healthy growth opportunities due to the technological advancement, new drug discovery techniques, patent expiry, and rising demand for specialized testing services among end users. “Chemistry services dominated the type segment” Based on type, the drug discovery services market is divided into chemistry services, and biology services. The chemistry services segment is further divided into synthetic chemistry services, analytical chemistry services, other chemistry services. The development of technologies like combinatorial chemistry and structure-based drug design has contributed to the growth of chemistry services. Chemistry’s extensive use in drug discovery particularly for lead molecule identification, lead modification or optimization, scale-up of the optimized lead for further drug development processes, and efficacy testing, has contributed to the growing demand for the segment. “The hit-to-lead identification dominated the process segment” Based on process, the drug discovery services market includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification services dominated the market. Growth in the hit-to-lead identification services market is predetermined due to its crucial place in drug discovery, being the maximum revenue-generating process. Many CROs offer these services to pharmaceutical companies. Moreover, key players are focusing on improving this critical step of drug discovery. “The small molecules dominated the drug type segment” Based on drug type, the drug discovery services market can be segmented into small molecules, and biologics. Small molecules would hold largest share in the market. The increasing growth of the small molecules can be attributed to several factors such as ease of working with, low costs, and increasing startup and new entrants focusing on small-molecule drug development. Small molecules can also easily enter the cells thanks to their low molecular weights. They may act on other molecules and kill cancer cells. As such, small molecules or small-molecule inhibitors are used extensively for many targeted therapies. “Cardiovascular diseases segment is anticipated to grow at a great pace” The therapeutic area segment is divided into oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas. The market for cardiovascular diseases is dominated due to high prevalence of cardiovascular diseases, rising geriatric population, and increasing partnerships between CROs and pharmaceutical & biotechnology companies. The integration of genetic and personalized medicine innovations will also support the growth of cardiovascular disease therapeutic discovery and development. “Pharmaceutical & Biotechnology Companies dominated the segment” Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic institutes, and other end users. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the drug discovery services market is due to the growing R&D expenditure for new molecules development, the increasing outsourcing of clinical services by these companies, and a strong pipeline of biotechnology companies to increase profit margins and reduce the time of drug development. “US to grow at the highest CAGR for North America drug discovery services market” The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the drug discovery services market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of key players. The country’s focus on R&D expenditure, and rapid growth in the biosimilar and biologics markets further boosts its leadership in the market. European drug discovery services market is experiencing steady growth, supported by demographic changes, the growing prevalence of diseases, and investments in R&D. In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the drug discovery services market. The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 – 55%, Tier 2 – 25%, and Tier 3 – 20% • By Designation: Directors - 45%, Managers - 30%, and Others - 25% • By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5% Thermo Fisher Scientific Inc. (US), Labcorp (US), Eurofins Scientific (Germany), Charles River Laboratories (US), WuXi AppTec (China), Pharmaron (China), Evotec (Germany), Syngene International Limited (India), Curia Global, Inc. (US), Aragen Life Sciences Ltd. (India), Jubilant Pharmova Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Frontage Holdings Corporation (US), GenScript (US), Sygnature Discovery (UK), and Piramal Enterprises Ltd. (India) are some of the key players in the drug discovery services market. Research Coverage: Drug discovery services market report is segmented based on process (target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation), by type [(chemistry services (synthetic chemistry services, analytical chemistry services, other chemistry services), and biology services (in vitro profiling services, toxicology services, and other biology services)], by drug type (small molecules, and biologics), by therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas), by end user (pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the drug discovery services and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, Increasing demand for outsourcing analytical testing services, Initiatives for research on rare diseases and orphan drugs, High cost of in-house drug development), restraints (Stringent regulations governing drug discovery and animal usages), opportunities (Growth in drugs and biologics market, Rising demand for specialized testing services among end users, Patent Expiry, High growth prospect in emerging markets) and Challenges (Economic uncertainties worldwide) influencing the growth of the market. • Product Development/Innovation: Detailed insights on upcoming technologies in drug discovery services, research and development activities, and new service launches in the drug discovery services market. • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions. • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi AppTec (China), and Pharmaron (China), and Labcorp (US), among others.
目錄 Table of Contents
1 INTRODUCTION 41 1.1 STUDY OBJECTIVES 41 1.2 MARKET DEFINITION 41 1.3 STUDY SCOPE 42 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 42 1.3.2 INCLUSIONS AND EXCLUSIONS 43 1.3.3 YEARS CONSIDERED 44 1.4 CURRENCY CONSIDERED 44 1.5 STAKEHOLDERS 44 1.6 SUMMARY OF CHANGES 45 2 RESEARCH METHODOLOGY 46 2.1 RESEARCH DATA 46 2.1.1 SECONDARY DATA 47 2.1.1.1 Objectives of secondary research 47 2.1.2 PRIMARY DATA 47 2.1.2.1 Objectives of primary research 48 2.2 MARKET SIZE ESTIMATION 49 2.2.1 GLOBAL MARKET ESTIMATION 49 2.2.2 SEGMENTAL MARKET ESTIMATION 52 2.3 GROWTH RATE PROJECTIONS 53 2.4 DATA TRIANGULATION 55 2.5 RESEARCH ASSUMPTIONS 56 2.6 RESEARCH LIMITATIONS 57 2.7 RISK ANALYSIS 57 3 EXECUTIVE SUMMARY 58 4 PREMIUM INSIGHTS 63 4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW 63 4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY, 2024 64 4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 65 4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER 65   5 MARKET OVERVIEW 66 5.1 INTRODUCTION 66 5.2 MARKET DYNAMICS 66 5.2.1 DRIVERS 67 5.2.1.1 Booming research & development expenditure in pharma-biotech sector 67 5.2.1.2 Growing pipeline of pharmaceutical and biopharmaceutical companies 68 5.2.1.3 Rising research on rare diseases and orphan drugs 69 5.2.1.4 Increasing reliance on outsourcing due to costly in-house drug development 70 5.2.2 RESTRAINTS 71 5.2.2.1 Stringent regulations 71 5.2.3 OPPORTUNITIES 72 5.2.3.1 Technological advancements and new drug discovery techniques 72 5.2.3.2 Rising demand for specialized testing services 73 5.2.3.3 Patent expiry of key biologics 73 5.2.3.4 High growth prospects in emerging markets 75 5.2.4 CHALLENGES 75 5.2.4.1 Economic uncertainties worldwide 75 5.2.5 MARKET TRENDS 76 5.2.5.1 Adoption of AI in drug discovery 76 5.2.5.2 Increased outsourcing in emerging economies 77 5.2.5.3 Consolidation of contract research organizations 78 5.2.5.4 Integrated end-to-end R&D service offerings 79 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80 5.4 PRICING ANALYSIS 80 5.4.1 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE 81 5.4.2 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION 82 5.5 SUPPLY CHAIN ANALYSIS 83 5.6 VALUE CHAIN ANALYSIS 84 5.7 ECOSYSTEM ANALYSIS 86 5.8 INVESTMENT AND FUNDING SCENARIO 89 5.9 TECHNOLOGY ANALYSIS 91 5.9.1 KEY TECHNOLOGIES 91 5.9.1.1 High-throughput screening 91 5.9.1.2 CRISPR gene editing 92 5.9.1.3 Structure-based drug design/Computer-aided drug design 92 5.9.2 COMPLEMENTARY TECHNOLOGIES 93 5.9.2.1 Automated liquid handling 93 5.9.2.2 In silico modeling 93 5.9.2.3 Patient-derived xenografts and organoids 93 5.9.3 ADJACENT TECHNOLOGIES 94 5.9.3.1 Nanotechnology 94 5.9.3.2 Synthetic biology 94 5.9.3.3 Organ-on-a-chip technology 95 5.10 PATENT ANALYSIS 95 5.11 KEY CONFERENCES AND EVENTS, 2025–2026 98 5.12 REGULATORY LANDSCAPE 99 5.12.1 REGULATORY FRAMEWORK 99 5.12.1.1 North America 99 5.12.1.1.1 US 99 5.12.1.1.2 Canada 100 5.12.1.2 Europe 100 5.12.1.2.1 UK 100 5.12.1.3 Asia Pacific 101 5.12.1.3.1 China 101 5.12.1.3.2 Japan 101 5.12.1.3.3 India 102 5.12.1.3.4 South Korea 102 5.12.1.3.5 Australia 102 5.12.1.3.6 Rest of Asia Pacific 103 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 5.13 PORTER’S FIVE FORCES ANALYSIS 105 5.13.1 BARGAINING POWER OF SUPPLIERS 107 5.13.2 BARGAINING POWER OF BUYERS 107 5.13.3 THREAT OF NEW ENTRANTS 107 5.13.4 THREAT OF SUBSTITUTES 107 5.13.5 INTENSITY OF COMPETITIVE RIVALRY 107 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 108 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 108 5.14.2 KEY BUYING CRITERIA, BY END USER 109 5.15 IMPACT OF AI ON DRUG DISCOVERY SERVICES MARKET 110 5.15.1 INTRODUCTION 110 5.15.2 MARKET POTENTIAL OF AI IN DRUG DISCOVERY SERVICES 110 5.15.3 AI USE CASES 111 5.15.4 FUTURE OF GENERATIVE AI IN DRUG DISCOVERY SERVICES MARKET 112 6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS 113 6.1 INTRODUCTION 114 6.2 TARGET SELECTION 115 6.2.1 INCREASING FOCUS ON IDENTIFYING POTENTIAL DRUG TARGETS TO BOLSTER GROWTH 115   6.3 TARGET VALIDATION 118 6.3.1 INCREASING EMPHASIS ON AVOIDING LATE-STAGE FAILURE TO PROMOTE GROWTH 118 6.4 HIT-TO-LEAD IDENTIFICATION 122 6.4.1 RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET 122 6.5 LEAD OPTIMIZATION 125 6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS IN CLINICAL TRIALS TO STIMULATE GROWTH 125 6.6 CANDIDATE VALIDATION 128 6.6.1 GROWING ATTENTION ON POTENCY AND SPECIFICITY OF DRUGS TO BOOST MARKET 128 7 DRUG DISCOVERY SERVICES MARKET, BY TYPE 132 7.1 INTRODUCTION 133 7.2 CHEMISTRY SERVICES 133 7.2.1 SYNTHETIC CHEMISTRY SERVICES 137 7.2.1.1 Increasing reliance on novel and efficient synthetic routes to augment growth 137 7.2.2 ANALYTICAL CHEMISTRY SERVICES 140 7.2.2.1 Rising demand for high-quality, safe, and effective drugs to support growth 140 7.2.3 OTHER CHEMISTRY SERVICES 143 7.3 BIOLOGY SERVICES 146 7.3.1 IN VITRO PROFILING SERVICES 150 7.3.1.1 Need for higher project productivity to speed up growth 150 7.3.2 TOXICOLOGY SERVICES 153 7.3.2.1 Growing emphasis on assessing safety profiles of new drug candidates to propel market 153 7.3.3 OTHER BIOLOGY SERVICES 156 8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE 159 8.1 INTRODUCTION 160 8.2 SMALL MOLECULES 160 8.2.1 INCREASING FOCUS ON OPTIMIZING SMALL-MOLECULE LEADS TO AMPLIFY GROWTH 160 8.3 BIOLOGICS 164 8.3.1 GROWING ADVANCEMENTS IN BIOTECHNOLOGY TO BOOST MARKET 164 9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA 168 9.1 INTRODUCTION 169 9.2 ONCOLOGY 170 9.2.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET 170 9.3 INFECTIOUS DISEASES 174 9.3.1 RISING EPIDEMIC OUTBREAKS TO ASSIST GROWTH 174 9.4 CARDIOVASCULAR DISEASES 177 9.4.1 HIGH MORTALITY RATES TO SPUR GROWTH 177 9.5 NEUROLOGICAL DISEASES 181 9.5.1 INCREASING RESEARCH & DEVELOPMENT INVESTMENTS FOR NEUROLOGICAL DISORDERS TO FAVOR GROWTH 181 9.6 IMMUNOLOGICAL DISORDERS 185 9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET 185 9.7 ENDOCRINE & METABOLIC DISORDERS 188 9.7.1 BOOMING DIABETIC POPULATION TO AID GROWTH 188 9.8 RESPIRATORY DISORDERS 192 9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH 192 9.9 DIGESTIVE SYSTEM DISEASES 195 9.9.1 CHANGING LIFESTYLE AND DIETARY HABITS TO PROMOTE GROWTH 195 9.10 GENITOURINARY DISEASES & WOMEN’S HEALTH 198 9.10.1 RISING AWARENESS ABOUT EARLY DIAGNOSIS AND TREATMENT TO SUSTAIN GROWTH 198 9.11 OTHER THERAPEUTIC AREAS 200 10 DRUG DISCOVERY SERVICES MARKET, BY END USER 204 10.1 INTRODUCTION 205 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 205 10.2.1 TIER 1 COMPANIES 209 10.2.1.1 Rising research & development activities to sustain growth 209 10.2.2 TIER 2 COMPANIES 212 10.2.2.1 Growing focus on specific therapeutic areas to drive market 212 10.2.3 TIER 3 COMPANIES 215 10.2.3.1 Increasing specialized drug discovery projects to expedite growth 215 10.3 ACADEMIC INSTITUTES 218 10.3.1 INCREASING COLLABORATIONS AMONG MARKET PLAYERS TO CONTRIBUTE TO GROWTH 218 10.4 OTHER END USERS 221 11 DRUG DISCOVERY SERVICES MARKET, BY REGION 224 11.1 INTRODUCTION 225 11.2 NORTH AMERICA 225 11.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA 230 11.2.2 US 231 11.2.2.1 Global leadership in pharmaceutical and biopharmaceutical research to aid growth 231 11.2.3 CANADA 235 11.2.3.1 Increasing initiatives for commercializing drugs to stimulate growth 235   11.3 EUROPE 239 11.3.1 MACROECONOMIC OUTLOOK OF EUROPE 243 11.3.2 GERMANY 244 11.3.2.1 Rising dominance of contract research organizations to encourage growth 244 11.3.3 UK 248 11.3.3.1 Increasing government-private sector collaborations to boost market 248 11.3.4 FRANCE 251 11.3.4.1 Growing number of oncology research projects to propel market 251 11.3.5 ITALY 255 11.3.5.1 High number of clinical trials and low drug approval time to promote growth 255 11.3.6 SPAIN 259 11.3.6.1 Rising elderly population to intensify growth 259 11.3.7 REST OF EUROPE 263 11.4 ASIA PACIFIC 267 11.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC 272 11.4.2 CHINA 273 11.4.2.1 Booming pharmaceutical industry to sustain growth 273 11.4.3 JAPAN 277 11.4.3.1 Increasing geriatric population to support growth 277 11.4.4 INDIA 281 11.4.4.1 Growing foreign direct investments to drive market 281 11.4.5 SOUTH KOREA 285 11.4.5.1 Favorable government support to accelerate growth 285 11.4.6 AUSTRALIA 289 11.4.6.1 Rising number of clinical trials to foster growth 289 11.4.7 REST OF ASIA PACIFIC 293 11.5 LATIN AMERICA 296 11.5.1 MACROECONOMIC OUTLOOK OF LATIN AMERICA 300 11.5.2 BRAZIL 301 11.5.2.1 Reduced timeline for drug approvals to favor growth 301 11.5.3 MEXICO 304 11.5.3.1 Favorable government policies to intensify growth 304 11.5.4 REST OF LATIN AMERICA 307 11.6 MIDDLE EAST 311 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 315 11.6.2 GCC COUNTRIES 316 11.6.2.1 Saudi Arabia 319 11.6.2.1.1 Booming healthcare expenditure to contribute to growth 319 11.6.2.2 UAE 323 11.6.2.2.1 Rising government initiatives for advanced healthcare to amplify growth 323 11.6.2.3 Other GCC Countries 327 11.6.3 REST OF MIDDLE EAST 331 11.7 AFRICA 335 11.7.1 RISING BURDEN OF CANCER AND CHRONIC DISEASES TO FACILITATE GROWTH 335 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 339 12 COMPETITIVE LANDSCAPE 340 12.1 INTRODUCTION 340 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 340 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET 341 12.3 REVENUE ANALYSIS, 2020−2024 344 12.4 MARKET SHARE ANALYSIS, 2024 345 12.5 COMPANY VALUATION AND FINANCIAL METRICS 348 12.6 BRAND/SERVICE COMPARISON 349 12.6.1 THERMO FISHER SCIENTIFIC INC. (US) 350 12.6.2 CHARLES RIVER LABORATORIES (US) 350 12.6.3 LABCORP (US) 350 12.6.4 WUXI APPTEC (CHINA) 350 12.6.5 PHARMARON (CHINA) 350 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 351 12.7.1 STARS 351 12.7.2 EMERGING LEADERS 351 12.7.3 PERVASIVE PLAYERS 351 12.7.4 PARTICIPANTS 351 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 353 12.7.5.1 Company footprint 353 12.7.5.2 Region footprint 354 12.7.5.3 Process footprint 355 12.7.5.4 Type footprint 356 12.7.5.5 Therapeutic area footprint 357 12.7.5.6 Drug type footprint 358 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 359 12.8.1 PROGRESSIVE COMPANIES 359 12.8.2 RESPONSIVE COMPANIES 359 12.8.3 DYNAMIC COMPANIES 359 12.8.4 STARTING BLOCKS 359 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES 361 12.8.5.1 Detailed list of key startups/SMEs 361 12.8.5.2 Competitive benchmarking of key startups/SMEs 362   12.9 COMPETITIVE SCENARIO 362 12.9.1 SERVICE LAUNCHES 362 12.9.2 DEALS 364 12.9.3 EXPANSIONS 365 12.9.4 OTHER DEVELOPMENTS 366 13 COMPANY PROFILES 367 13.1 KEY PLAYERS 367 13.1.1 THERMO FISHER SCIENTIFIC INC. 367 13.1.1.1 Business overview 367 13.1.1.2 Services offered 369 13.1.1.3 Recent developments 369 13.1.1.3.1 Service launches 369 13.1.1.3.2 Deals 370 13.1.1.3.3 Expansions 370 13.1.1.4 MnM view 371 13.1.1.4.1 Key strengths 371 13.1.1.4.2 Strategic choices 371 13.1.1.4.3 Weaknesses and competitive threats 371 13.1.2 CHARLES RIVER LABORATORIES 372 13.1.2.1 Business overview 372 13.1.2.2 Services offered 374 13.1.2.3 Recent developments 375 13.1.2.3.1 Service launches 375 13.1.2.3.2 Deals 375 13.1.2.4 MnM view 377 13.1.2.4.1 Key strengths 377 13.1.2.4.2 Strategic choices 377 13.1.2.4.3 Weaknesses and competitive threats 377 13.1.3 WUXI APPTEC 378 13.1.3.1 Business overview 378 13.1.3.2 Services offered 380 13.1.3.3 Recent developments 381 13.1.3.3.1 Expansions 381 13.1.3.4 MnM view 382 13.1.3.4.1 Key strengths 382 13.1.3.4.2 Strategic choices 382 13.1.3.4.3 Weaknesses and competitive threats 382 13.1.4 PHARMARON 383 13.1.4.1 Business overview 383 13.1.4.2 Services offered 384 13.1.4.2.1 Deals 387 13.1.4.3 MnM view 388 13.1.4.3.1 Key strengths 388 13.1.4.3.2 Strategic choices 388 13.1.4.3.3 Weaknesses and competitive threats 388 13.1.5 LABCORP 389 13.1.5.1 Business overview 389 13.1.5.2 Services offered 391 13.1.5.3 Recent developments 391 13.1.5.3.1 Deals 391 13.1.5.3.2 Expansions 392 13.1.5.4 MnM view 392 13.1.5.4.1 Key strengths 392 13.1.5.4.2 Strategic choices 393 13.1.5.4.3 Weaknesses and competitive threats 393 13.1.6 EVOTEC 394 13.1.6.1 Business overview 394 13.1.6.2 Services offered 395 13.1.6.3 Recent developments 396 13.1.6.3.1 Deals 396 13.1.6.3.2 Expansions 398 13.1.6.3.3 Other developments 398 13.1.7 SYNGENE INTERNATIONAL LIMITED 399 13.1.7.1 Business overview 399 13.1.7.2 Services offered 400 13.1.7.3 Recent developments 401 13.1.7.3.1 Deals 401 13.1.7.3.2 Expansions 401 13.1.8 EUROFINS SCIENTIFIC 402 13.1.8.1 Business overview 402 13.1.8.2 Services offered 403 13.1.8.3 Recent developments 404 13.1.8.3.1 Service launches 404 13.1.8.3.2 Deals 405 13.1.8.3.3 Expansions 405 13.1.9 JUBILANT PHARMOVA LIMITED 406 13.1.9.1 Business overview 406 13.1.9.2 Services offered 407 13.1.9.3 Recent developments 408 13.1.9.3.1 Deals 408 13.1.9.3.2 Expansions 409   13.1.10 GENSCRIPT 410 13.1.10.1 Business overview 410 13.1.10.2 Services offered 411 13.1.10.3 Recent developments 412 13.1.10.3.1 Service launches 412 13.1.10.3.2 Deals 412 13.1.11 FRONTAGE HOLDINGS CORPORATION 413 13.1.11.1 Business overview 413 13.1.11.2 Services offered 415 13.1.11.3 Recent developments 416 13.1.11.3.1 Service launches 416 13.1.11.3.2 Deals 416 13.1.11.3.3 Expansions 417 13.1.12 PIRAMAL ENTERPRISES LTD. 418 13.1.12.1 Business overview 418 13.1.12.2 Services offered 419 13.1.12.3 Recent developments 420 13.1.12.3.1 Expansions 420 13.1.13 AURIGENE PHARMACEUTICAL SERVICES LTD. 421 13.1.13.1 Business overview 421 13.1.13.2 Services offered 422 13.1.13.3 Recent developments 423 13.1.13.3.1 Service launches 423 13.1.13.3.2 Deals 423 13.1.13.3.3 Expansions 424 13.1.14 CURIA GLOBAL, INC. 425 13.1.14.1 Business overview 425 13.1.14.2 Services offered 425 13.1.14.3 Recent developments 426 13.1.14.3.1 Service launches 426 13.1.14.3.2 Deals 427 13.1.14.3.3 Other developments 427 13.1.15 SHANGHAI MEDICILON INC. 428 13.1.15.1 Business overview 428 13.1.15.2 Services offered 428 13.1.15.3 Recent developments 429 13.1.15.3.1 Deals 429 13.1.15.3.2 Expansions 429 13.1.16 SYGNATURE DISCOVERY 430 13.1.16.1 Business overview 430 13.1.16.2 Services offered 430 13.1.16.2.1 Deals 431 13.1.16.2.2 Expansions 432 13.2 OTHER PLAYERS 433 13.2.1 SELVITA 433 13.2.2 VIVA BIOTECH 434 13.2.3 TCG LIFESCIENCES PVT. LTD. 435 13.2.4 SHANGHAI CHEMPARTNER 436 13.2.5 DOMAINEX 437 13.2.6 NUVISAN GMBH 438 13.2.7 DALTON PHARMA SERVICES 439 13.2.8 ARAGEN LIFE SCIENCES LTD. 440 13.2.9 ONCODESIGN SERVICES 441 14 APPENDIX 442 14.1 DISCUSSION GUIDE 442 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 446 14.3 CUSTOMIZATION OPTIONS 448 14.4 RELATED REPORTS 449 14.5 AUTHOR DETAILS 450
圖表清單 List of Tables & Figures
TABLE 1 DRUG DISCOVERY SERVICES MARKET: INCLUSIONS AND EXCLUSIONS 43 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 54 TABLE 3 DRUG DISCOVERY SERVICES MARKET: RISK ANALYSIS 57 TABLE 4 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 67 TABLE 5 US: BIOLOGICS GOING OFF PATENT, 2025–2030 74 TABLE 6 DRUG DISCOVERY SERVICES MARKET: PROMINENT ACQUISITIONS, 2021–2024 78 TABLE 7 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE, 2024 (USD) 81 TABLE 8 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION, 2024 (USD) 82 TABLE 9 DRUG DISCOVERY SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 88 TABLE 10 INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021−2025 89 TABLE 11 DRUG DISCOVERY SERVICES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021–2024 97 TABLE 12 DRUG DISCOVERY SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 98 TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 17 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 106 TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 108 TABLE 19 KEY BUYING CRITERIA, BY END USER 109 TABLE 20 KEY COMPANIES IMPLEMENTING AI 111 TABLE 21 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 114 TABLE 22 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 23 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 24 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 25 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 26 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 27 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 28 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 29 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 30 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 31 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 32 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 33 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 34 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 35 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 36 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 37 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 38 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 39 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 40 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 41 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 42 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 43 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 44 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 45 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 46 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 47 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 48 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 49 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 50 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 51 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 52 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 53 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 54 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 55 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 56 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 57 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 133 TABLE 58 DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 59 DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 60 NORTH AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 61 EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 62 ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 63 LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 64 MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 65 GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 66 DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 67 NORTH AMERICA: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 68 EUROPE: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 69 ASIA PACIFIC: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 70 LATIN AMERICA: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 71 MIDDLE EAST: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 72 GCC COUNTRIES: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 73 DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 74 NORTH AMERICA: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 75 EUROPE: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 76 ASIA PACIFIC: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 77 LATIN AMERICA: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 78 MIDDLE EAST: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 79 GCC COUNTRIES: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 80 OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 81 NORTH AMERICA: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKE, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 82 EUROPE: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 83 ASIA PACIFIC: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 84 LATIN AMERICA: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 85 MIDDLE EAST: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 86 GCC COUNTRIES: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 87 DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 147 TABLE 88 DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 89 NORTH AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 90 EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 91 ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 92 LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 93 MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 94 GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 95 DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 96 NORTH AMERICA: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 97 EUROPE: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 98 ASIA PACIFIC: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 99 LATIN AMERICA: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 100 MIDDLE EAST: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 101 GCC COUNTRIES: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 102 DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 103 NORTH AMERICA: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 104 EUROPE: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 105 ASIA PACIFIC: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 106 LATIN AMERICA: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 107 MIDDLE EAST: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 108 GCC COUNTRIES: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 109 OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 110 NORTH AMERICA: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 111 EUROPE: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 112 ASIA PACIFIC: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 113 LATIN AMERICA: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 114 MIDDLE EAST: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 115 GCC COUNTRIES: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 116 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 160 TABLE 117 DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 118 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 119 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 120 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 121 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 122 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 123 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 124 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 125 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 126 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 127 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 128 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 129 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 130 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 131 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 169 TABLE 132 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY, 2024 170 TABLE 133 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 134 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 135 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 136 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 137 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 138 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 139 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 140 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 141 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 142 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 143 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 144 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 145 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 146 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 147 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES, 2024 177 TABLE 148 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 149 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 150 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 151 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 152 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 153 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 180 TABLE 154 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 155 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS, 2024 182 TABLE 156 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 157 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 158 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 159 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 160 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 161 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 184 TABLE 162 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 163 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS, 2024 185 TABLE 164 DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 165 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 166 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 167 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 168 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 169 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 187 TABLE 170 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 171 DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 189 TABLE 172 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 173 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 174 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 175 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 176 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 191 TABLE 177 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 178 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS, 2024 192 TABLE 179 DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION) 193 TABLE 180 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 181 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 182 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 183 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 184 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 185 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 186 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 187 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 188 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 189 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 190 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 191 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2023–2030 (USD MILLION) 197 TABLE 192 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 193 DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 194 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 195 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 196 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 197 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 198 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION) 200 TABLE 199 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 200 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 201 TABLE 201 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 202 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 203 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 204 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 205 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 203 TABLE 206 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 207 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 205 TABLE 208 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 206 TABLE 209 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 210 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 211 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 212 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 213 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 208 TABLE 214 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 215 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 209 TABLE 216 TOP REVENUE-GENERATING PHARMA COMPANIES, 2023 209 TABLE 217 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2023–2030 (USD MILLION) 210 TABLE 218 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 219 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 220 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 221 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 222 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2023–2030 (USD MILLION) 211 TABLE 223 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 224 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2023–2030 (USD MILLION) 212 TABLE 225 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 226 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 227 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 228 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 229 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2023–2030 (USD MILLION) 214 TABLE 230 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 231 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2023–2030 (USD MILLION) 215 TABLE 232 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 233 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 234 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 235 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 236 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2023–2030 (USD MILLION) 217 TABLE 237 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 238 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 218 TABLE 239 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 240 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 241 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 242 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 243 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 220 TABLE 244 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 245 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 221 TABLE 246 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 247 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 248 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 249 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 250 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 223 TABLE 251 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 252 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 225 TABLE 253 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 227 TABLE 254 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 227 TABLE 255 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 256 NORTH AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 257 NORTH AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 258 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 228 TABLE 259 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 229 TABLE 260 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 229 TABLE 261 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 262 KEY MACROECONOMIC INDICATORS OF NORTH AMERICA 230 TABLE 263 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 232 TABLE 264 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 265 US: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 266 US: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 267 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 233 TABLE 268 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 234 TABLE 269 US: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 234 TABLE 270 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 271 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 236 TABLE 272 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 273 CANADA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 274 CANADA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 275 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 237 TABLE 276 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 238 TABLE 277 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 278 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 279 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 240 TABLE 280 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 240 TABLE 281 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 282 EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 283 EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 284 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 241 TABLE 285 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 242 TABLE 286 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 242 TABLE 287 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 288 KEY MACROECONOMIC INDICATORS OF EUROPE 244 TABLE 289 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 245 TABLE 290 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 291 GERMANY: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 292 GERMANY: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 293 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 246 TABLE 294 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 247 TABLE 295 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 296 GERMANY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 297 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 248 TABLE 298 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 299 UK: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 300 UK: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 301 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 250 TABLE 302 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 250 TABLE 303 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 251 TABLE 304 UK: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 305 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 252 TABLE 306 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 307 FRANCE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 308 FRANCE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 309 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 253 TABLE 310 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 254 TABLE 311 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 254 TABLE 312 FRANCE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 313 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 256 TABLE 314 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 315 ITALY: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 316 ITALY: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 317 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 257 TABLE 318 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 258 TABLE 319 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 258 TABLE 320 ITALY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 321 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 260 TABLE 322 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 323 SPAIN: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 324 SPAIN: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 325 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 261 TABLE 326 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 262 TABLE 327 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 262 TABLE 328 SPAIN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 329 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 264 TABLE 330 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 331 REST OF EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 332 REST OF EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 333 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 265 TABLE 334 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 266 TABLE 335 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 266 TABLE 336 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 337 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 269 TABLE 338 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 269 TABLE 339 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 340 ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 341 ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 342 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 271 TABLE 343 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 271 TABLE 344 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 272 TABLE 345 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 346 KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC 273 TABLE 347 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 274 TABLE 348 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 349 CHINA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 350 CHINA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 351 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 275 TABLE 352 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 276 TABLE 353 CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 276 TABLE 354 CHINA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 277 TABLE 355 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 278 TABLE 356 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 357 JAPAN: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 358 JAPAN: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 359 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 279 TABLE 360 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 280 TABLE 361 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 280 TABLE 362 JAPAN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 363 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 282 TABLE 364 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 365 INDIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 366 INDIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 283 TABLE 367 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 283 TABLE 368 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 284 TABLE 369 INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 284 TABLE 370 INDIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 371 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 286 TABLE 372 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 373 SOUTH KOREA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 374 SOUTH KOREA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 375 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 287 TABLE 376 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 288 TABLE 377 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 288 TABLE 378 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 379 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 290 TABLE 380 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 290 TABLE 381 AUSTRALIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 290 TABLE 382 AUSTRALIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 383 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 291 TABLE 384 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 292 TABLE 385 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 292 TABLE 386 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 387 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 293 TABLE 388 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 294 TABLE 389 REST OF ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 294 TABLE 390 REST OF ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 294 TABLE 391 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 295 TABLE 392 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 295 TABLE 393 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 296 TABLE 394 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 395 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 297 TABLE 396 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 297 TABLE 397 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 297 TABLE 398 LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 399 LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 400 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 298 TABLE 401 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 299 TABLE 402 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 299 TABLE 403 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 300 TABLE 404 KEY MACROECONOMIC INDICATORS OF LATIN AMERICA 300 TABLE 405 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 301 TABLE 406 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 407 BRAZIL: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 408 BRAZIL: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 409 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 302 TABLE 410 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 303 TABLE 411 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 303 TABLE 412 BRAZIL: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 413 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 304 TABLE 414 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 305 TABLE 415 MEXICO: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 305 TABLE 416 MEXICO: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 305 TABLE 417 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 306 TABLE 418 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 306 TABLE 419 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 307 TABLE 420 MEXICO: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 421 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 308 TABLE 422 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 423 REST OF LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 424 REST OF LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 425 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 309 TABLE 426 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 310 TABLE 427 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 310 TABLE 428 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 311 TABLE 429 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 312 TABLE 430 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 312 TABLE 431 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 312 TABLE 432 MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 433 MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 434 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 313 TABLE 435 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 314 TABLE 436 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 314 TABLE 437 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 438 KEY MACROECONOMIC INDICATORS OF MIDDLE EAST 315 TABLE 439 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 316 TABLE 440 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 316 TABLE 441 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 442 GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 443 GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 444 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 318 TABLE 445 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 318 TABLE 446 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 319 TABLE 447 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 448 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 320 TABLE 449 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 450 SAUDI ARABIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 451 SAUDI ARABIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 321 TABLE 452 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 321 TABLE 453 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 322 TABLE 454 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 322 TABLE 455 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 456 UAE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 324 TABLE 457 UAE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 458 UAE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 459 UAE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 460 UAE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 325 TABLE 461 UAE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 326 TABLE 462 UAE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 326 TABLE 463 UAE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 327 TABLE 464 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 328 TABLE 465 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 466 OTHER GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 467 OTHER GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 468 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 329 TABLE 469 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 330 TABLE 470 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 330 TABLE 471 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 331 TABLE 472 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 332 TABLE 473 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 332 TABLE 474 REST OF MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 332 TABLE 475 REST OF MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 333 TABLE 476 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 333 TABLE 477 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 334 TABLE 478 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 334 TABLE 479 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 335 TABLE 480 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 336 TABLE 481 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 482 AFRICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 483 AFRICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 337 TABLE 484 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 337 TABLE 485 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 338 TABLE 486 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 338 TABLE 487 AFRICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION) 339 TABLE 488 KEY MACROECONOMIC INDICATORS OF AFRICA 339 TABLE 489 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2021−2024 341 TABLE 490 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION 346 TABLE 491 DRUG DISCOVERY SERVICES MARKET: REGION FOOTPRINT 354 TABLE 492 DRUG DISCOVERY SERVICES MARKET: PROCESS FOOTPRINT 355 TABLE 493 DRUG DISCOVERY SERVICES MARKET: TYPE FOOTPRINT 356 TABLE 494 DRUG DISCOVERY SERVICES MARKET: THERAPEUTIC AREA FOOTPRINT 357 TABLE 495 DRUG DISCOVERY SERVICES MARKET: DRUG TYPE FOOTPRINT 358 TABLE 496 DRUG DISCOVERY SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 361 TABLE 497 DRUG DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 362 TABLE 498 DRUG DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 363 TABLE 499 DRUG DISCOVERY SERVICES MARKET: DEALS, JANUARY 2021–JANUARY 2025 364 TABLE 500 DRUG DISCOVERY SERVICES MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025 365 TABLE 501 DRUG DISCOVERY SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 366 TABLE 502 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 367 TABLE 503 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 369 TABLE 504 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 369 TABLE 505 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2025 370 TABLE 506 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025 370 TABLE 507 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 372 TABLE 508 CHARLES RIVER LABORATORIES: SERVICES OFFERED 374 TABLE 509 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 375 TABLE 510 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–JANUARY 2025 375 TABLE 511 WUXI APPTEC: COMPANY OVERVIEW 378 TABLE 512 WUXI APPTEC: SERVICES OFFERED 380 TABLE 513 WUXI APPTEC: EXPANSIONS, JANUARY 2021–JANUARY 2025 381 TABLE 514 PHARMARON: COMPANY OVERVIEW 383 TABLE 515 PHARMARON: SERVICES OFFERED 384 TABLE 516 PHARMARON: DEALS, JANUARY 2021–JANUARY 2025 387 TABLE 517 LABCORP: COMPANY OVERVIEW 389 TABLE 518 LABCORP: SERVICES OFFERED 391 TABLE 519 LABCORP: DEALS, JANUARY 2021–JANUARY 2025 391 TABLE 520 LABCORP: EXPANSIONS, JANUARY 2021–JANUARY 2025 392 TABLE 521 EVOTEC: COMPANY OVERVIEW 394 TABLE 522 EVOTEC: SERVICES OFFERED 395 TABLE 523 EVOTEC: DEALS, JANUARY 2021–JANUARY 2025 396 TABLE 524 EVOTEC: EXPANSIONS, JANUARY 2021–JANUARY 2025 398 TABLE 525 EVOTEC: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 398 TABLE 526 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW 399 TABLE 527 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED 400 TABLE 528 SYNGENE INTERNATIONAL LIMITED: DEALS, JANUARY 2021–JANUARY 2025 401 TABLE 529 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2021–JANUARY 2025 401 TABLE 530 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 402 TABLE 531 EUROFINS SCIENTIFIC: SERVICES OFFERED 403 TABLE 532 EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 404 TABLE 533 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–JANUARY 2025 405 TABLE 534 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021–JANUARY 2025 405 TABLE 535 JUBILANT PHARMOVA LIMITED: COMPANY OVERVIEW 406 TABLE 536 JUBILANT PHARMOVA LIMITED: SERVICES OFFERED 407 TABLE 537 JUBILANT PHARMOVA LIMITED: DEALS, JANUARY 2021–JANUARY 2025 408 TABLE 538 JUBILANT PHARMOVA LIMITED: EXPANSIONS, JANUARY 2021–JANUARY 2025 409 TABLE 539 GENSCRIPT: COMPANY OVERVIEW 410 TABLE 540 GENSCRIPT: SERVICES OFFERED 411 TABLE 541 GENSCRIPT: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 412 TABLE 542 GENSCRIPT: DEALS, JANUARY 2021–JANUARY 2025 412 TABLE 543 FRONTAGE HOLDINGS CORPORATION: COMPANY OVERVIEW 413 TABLE 544 FRONTAGE HOLDINGS CORPORATION: SERVICES OFFERED 415 TABLE 545 FRONTAGE HOLDINGS CORPORATION: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 416 TABLE 546 FRONTAGE HOLDINGS CORPORATION: DEALS, JANUARY 2021–JANUARY 2025 416 TABLE 547 FRONTAGE HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025 417 TABLE 548 PIRAMAL ENTERPRISES LTD.: COMPANY OVERVIEW 418 TABLE 549 PIRAMAL ENTERPRISES LTD.: SERVICES OFFERED 419 TABLE 550 PIRAMAL ENTERPRISES LTD.: EXPANSIONS, JANUARY 2021–JANUARY 2025 420 TABLE 551 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW 421 TABLE 552 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED 422 TABLE 553 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 423 TABLE 554 AURIGENE PHARMACEUTICAL SERVICES LTD.: DEALS, JANUARY 2021–JANUARY 2025 423 TABLE 555 AURIGENE PHARMACEUTICAL SERVICES LTD.: EXPANSIONS, JANUARY 2021–JANUARY 2025 424 TABLE 556 CURIA GLOBAL, INC.: COMPANY OVERVIEW 425 TABLE 557 CURIA GLOBAL, INC.: SERVICES OFFERED 425 TABLE 558 CURIA GLOBAL, INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 426 TABLE 559 CURIA GLOBAL, INC.: DEALS, JANUARY 2021–JANUARY 2025 427 TABLE 560 CURIA GLOBAL, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 427 TABLE 561 SHANGHAI MEDICILON INC.: COMPANY OVERVIEW 428 TABLE 562 SHANGHAI MEDICILON INC.: SERVICES OFFERED 428 TABLE 563 SHANGHAI MEDICILON INC.: DEALS, JANUARY 2021–JANUARY 2025 429 TABLE 564 SHANGHAI MEDICILON INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025 429 TABLE 565 SYGNATURE DISCOVERY: COMPANY OVERVIEW 430 TABLE 566 SYGNATURE DISCOVERY: SERVICES OFFERED 430 TABLE 567 SYGNATURE DISCOVERY: DEALS, JANUARY 2021–JANUARY 2025 431 TABLE 568 SYGNATURE DISCOVERY: EXPANSIONS, JANUARY 2021–JANUARY 2025 432 TABLE 569 SELVITA: COMPANY OVERVIEW 433 TABLE 570 VIVA BIOTECH: COMPANY OVERVIEW 434 TABLE 571 TCG LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW 435 TABLE 572 SHANGHAI CHEMPARTNER: COMPANY OVERVIEW 436 TABLE 573 DOMAINEX: COMPANY OVERVIEW 437 TABLE 574 NUVISAN GMBH: COMPANY OVERVIEW 438 TABLE 575 DALTON PHARMA SERVICES: COMPANY OVERVIEW 439 TABLE 576 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW 440 TABLE 577 ONCODESIGN SERVICES: COMPANY OVERVIEW 441 _ FIGURE 1 DRUG DISCOVERY SERVICES MARKET SEGMENTATION AND REGIONAL SCOPE 42 FIGURE 2 DRUG DISCOVERY SERVICES MARKET: YEARS CONSIDERED 44 FIGURE 3 DRUG DISCOVERY SERVICES MARKET: RESEARCH DESIGN 46 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION 48 FIGURE 5 GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION, 2024 49 FIGURE 6 COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024 50 FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES, 2024 50 FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARIES 52 FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 52 FIGURE 10 DRUG DISCOVERY SERVICES MARKET: CAGR PROJECTIONS, 2025–2030 54 FIGURE 11 DRUG DISCOVERY SERVICES MARKET: DATA TRIANGULATION 55 FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2025 VS. 2030 (USD MILLION) 58 FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 59 FIGURE 14 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2025 VS. 2030 (USD MILLION) 59 FIGURE 15 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 60 FIGURE 16 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 61 FIGURE 17 REGIONAL SNAPSHOT OF DRUG DISCOVERY SERVICES MARKET, 2025–2030 62 FIGURE 18 INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET 63 FIGURE 19 SMALL MOLECULES SEGMENT AND US LED NORTH AMERICAN DRUG DISCOVERY SERVICES MARKET IN 2024 64 FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 65 FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024 65 FIGURE 22 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66 FIGURE 23 GLOBAL PHARMACEUTICAL R&D SPENDING, 2016–2030 68 FIGURE 24 ACTIVE PHARMACEUTICAL PIPELINE, 2014–2024 69 FIGURE 25 NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS, 2013–2023 70 FIGURE 26 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2013–2023 (USD BILLION) 71 FIGURE 27 NEW REVENUE POCKETS FOR PLAYERS IN DRUG DISCOVERY SERVICES MARKET 80 FIGURE 28 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE, 2024 (USD) 81 FIGURE 29 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION, 2024 (USD) 82 FIGURE 30 DRUG DISCOVERY SERVICES MARKET: SUPPLY CHAIN ANALYSIS 84 FIGURE 31 DRUG DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS 85 FIGURE 32 DRUG DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS 88 FIGURE 33 INVESTMENT AND FUNDING SCENARIO, 2022–2025 91 FIGURE 34 DRUG DISCOVERY SERVICES MARKET: PATENT ANALYSIS, 2014–2024 96 FIGURE 35 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 106 FIGURE 36 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 108 FIGURE 37 KEY BUYING CRITERIA, BY END USER 109 FIGURE 38 AI USE CASES 111 FIGURE 39 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 188 FIGURE 40 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2024) 226 FIGURE 41 DISTRIBUTION OF PHARMACEUTICAL R&D COMPANIES, BY COUNTRY/REGION, 2023 VS. 2024 231 FIGURE 42 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2024) 268 FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2020−2024 345 FIGURE 44 MARKET SHARE ANALYSIS OF DRUG DISCOVERY SERVICES MARKET, 2024 346 FIGURE 45 RANKING OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2024 347 FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 348 FIGURE 47 EV/EBITDA OF KEY PLAYERS, 2024 348 FIGURE 48 DRUG DISCOVERY SERVICES MARKET: BRAND/SERVICE COMPARISON 349 FIGURE 49 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 352 FIGURE 50 DRUG DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT 353 FIGURE 51 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 360 FIGURE 52 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 368 FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023) 373 FIGURE 54 WUXI APPTEC: COMPANY SNAPSHOT (2023) 379 FIGURE 55 PHARMARON: COMPANY SNAPSHOT (2023) 384 FIGURE 56 LABCORP: COMPANY SNAPSHOT (2023) 390 FIGURE 57 EVOTEC: COMPANY SNAPSHOT (2023) 395 FIGURE 58 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2023) 399 FIGURE 59 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 402 FIGURE 60 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2023) 407 FIGURE 61 GENSCRIPT: COMPANY SNAPSHOT (2023) 411 FIGURE 62 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023) 414 FIGURE 63 PIRAMAL ENTERPRISES LTD.: COMPANY SNAPSHOT (2023) 419 FIGURE 64 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2023) 422

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們